filovirus
marburg
viru
ebola
viru
caus
sever
hemorrhag
fever
high
mortal
rate
human
nonhuman
primat
among
mostpromis
filoviru
vaccin
develop
system
base
recombin
vesicular
stomat
viru
rvsv
express
singl
filoviru
glycoprotein
gp
place
vsv
glycoprotein
g
importantli
singl
inject
blend
rvsvbase
filoviru
vaccin
shown
complet
protect
nonhuman
primat
marburg
viru
differ
speci
ebola
viru
rvsvbase
vaccin
also
shown
util
administ
postexposur
treatment
filoviru
infect
rvsvbase
ebola
viru
vaccin
recent
use
treat
potenti
laboratori
exposur
review
histori
rvsvbase
vaccin
pivot
anim
studi
show
util
combat
ebola
marburg
viru
infect
marburg
viru
marv
ebola
viru
ebov
signific
human
pathogen
present
public
health
concern
emerg
reemerg
virus
potenti
biolog
weapon
vaccin
antivir
drug
marv
ebov
current
licens
avail
human
use
although
marburg
ebola
hemorrhag
fever
hf
rare
diseas
prevent
vaccin
could
import
sever
group
includ
risk
group
filoviru
outbreak
endem
area
subsaharan
africa
medic
personnel
patient
care
personnel
famili
member
nation
intern
healthcar
worker
outbreak
respons
personnel
laboratori
worker
conduct
research
filovirus
militari
servic
personnel
suscept
filovirus
use
bioweapon
properti
filoviru
vaccin
requir
divers
group
may
vari
exampl
although
laboratori
healthcar
worker
militari
personnel
stabl
set
defin
risk
may
candid
multidos
vaccin
outbreak
set
requir
protect
rapidli
confer
singl
administr
ideal
vaccin
meet
need
would
singl
administr
rapidli
confer
longterm
protect
littl
filoviru
viremia
speci
ebov
pathogen
human
well
divers
strain
marv
remark
progress
made
preced
decad
develop
candid
prevent
vaccin
filovirus
nonhuman
primat
nhp
model
least
differ
vaccin
system
shown
promis
complet
protect
nhp
ebov
marv
infect
tabl
among
prospect
vaccin
shown
efficaci
nhp
model
filovir
hf
candid
base
replicationdefect
adenoviru
serotyp
recombin
vesicular
stomat
viru
rvsv
provid
complet
protect
nhp
administ
singl
inject
review
focus
rvsvbase
filoviru
vaccin
marburg
viru
marv
ebola
viru
ebov
caus
agent
marburg
ebola
hf
repres
genera
compris
famili
filovirida
marburgviru
genu
contain
singl
speci
lake
victoria
marburgviru
marv
wherea
ebolaviru
genu
compris
recogn
speci
sudan
ebolaviru
sebov
zair
ebolaviru
zebov
divoir
ebolaviru
also
known
refer
ivori
coast
ebolaviru
icebov
reston
ebolaviru
rebov
put
fifth
speci
bundigbugyo
ebolaviru
bebov
associ
outbreak
uganda
marv
zebov
sebov
bebov
import
human
pathogen
casefat
rate
frequent
rang
marv
zebov
around
sebov
review
base
singl
outbreak
newli
discov
bebov
appear
less
pathogen
casefat
rate
icebov
caus
death
chimpanze
sever
nonleth
human
infect
singl
case
republ
divoir
rebov
lethal
macaqu
yet
report
caus
diseas
human
ebov
marv
filament
envelop
nonseg
negativesens
rna
virus
genom
approxim
kb
viru
encod
structur
gene
product
follow
order
nucleoprotein
np
virion
protein
vp
glycoprotein
gp
polymeras
l
addit
ebov
express
least
nonstructur
solubl
gp
sgp
encod
gp
gene
gp
variabl
contribut
viral
protein
np
appear
key
immunogen
protein
vaccin
protect
vsv
prototyp
member
famili
rhabdovirida
famili
negativestrand
rna
virus
simpl
genom
organ
encod
structur
protein
order
nucleocapsid
n
phosphoprotein
p
matrix
glycoprotein
g
rnadepend
rna
polymeras
l
vsv
caus
diseas
cattl
hors
deer
pig
character
vesicul
ulcer
tongu
oral
tissu
feet
teat
infect
anim
typic
recov
within
week
wherea
natur
occur
vsv
infect
human
rare
infect
report
person
directli
expos
infect
livestock
live
within
endem
region
accident
expos
laboratori
vsv
infect
human
usual
either
asymptomat
caus
mild
influenzalik
ill
among
small
anim
mice
shown
util
model
evalu
vsv
pathogenesi
exampl
intranas
infect
mice
vsv
result
signific
weight
loss
preinfect
bodi
weight
day
infect
weight
loss
conveni
measur
vsv
pathogenesi
also
intracerebr
inocul
mice
vsv
produc
signific
neuropatholog
shown
util
neurovirul
assay
previou
studi
demonstr
rhabdovirus
util
express
vector
potenti
use
viral
vaccin
vector
live
viral
vaccin
tradit
offer
highest
level
protect
viral
infect
vaccin
induc
strong
cellular
humor
host
immun
respons
result
intracellular
synthesi
specif
antigen
high
level
prolong
period
last
year
rose
colleagu
pioneer
use
rvsv
prototyp
member
rhabdovirida
famili
express
vaccin
vector
certain
characterist
vsv
suggest
rvsv
express
foreign
viral
gene
would
good
vaccin
candid
vsv
grow
high
titer
mani
cell
line
vitro
plaqueform
unit
pfu
ml
propag
almost
mammalian
cell
vsv
elicit
strong
humor
cellular
respons
vivo
abl
elicit
mucos
system
immun
addit
extrem
low
percentag
vsv
seroposit
gener
popul
lack
seriou
pathogen
human
possibl
advantag
use
rvsv
vaccin
human
importantli
singlestrand
rna
genom
vsv
undergo
reassort
therefor
lack
potenti
undergo
genet
shift
vivo
furthermor
vsv
replic
within
cytoplasm
infect
cell
undergo
genet
recombin
decad
ago
procedur
gener
replicationcompet
negativestrand
rvsv
entir
complementari
dna
establish
genet
flexibl
vsv
allow
develop
rvsv
express
foreign
viral
protein
high
level
sever
differ
strategi
employ
develop
candid
replicationcompet
rvsvbase
vaccin
adopt
measur
enhanc
safeti
exampl
previou
studi
shown
pathogenesi
neurovirul
vsv
mice
directli
associ
vsv
g
studi
also
shown
vsv
g
determin
pathogenesi
swine
attenu
rvsv
vector
group
made
mutat
truncat
vsv
g
cytoplasm
domain
amino
acid
action
result
abrog
pathogenesi
mice
anoth
approach
develop
gp
exchang
vector
vsv
g
complet
delet
replac
foreign
gp
gener
rvsv
util
prevent
viru
infect
shown
sever
studi
rose
colleagu
demonstr
live
attenu
rvsv
express
human
immunodefici
viru
hiv
envelop
env
core
gag
protein
protect
rhesu
monkey
aid
follow
challeng
pathogen
aid
viru
similarli
robert
cowork
develop
rvsv
vector
express
influenza
hemagglutinin
ha
protein
complet
attenu
pathogenesi
mous
model
nonpathogen
vaccin
also
provid
complet
protect
lethal
influenza
viru
challeng
moreov
anoth
vaccin
vsv
g
delet
express
ha
rvsvngha
also
protect
nonpathogen
addit
advantag
induc
neutral
antibodi
vector
importantli
mice
immun
rvsvngha
subsequ
challeng
wildtyp
vsv
develop
neutral
antibodi
titer
vsv
antibodi
direct
vsv
g
subsequ
shown
gp
exchang
vector
allow
effect
boost
gener
neutral
antibodi
primari
isol
hiv
type
togeth
studi
indic
rvsvng
reusabl
vector
particularli
import
advantag
vaccin
platform
use
strategi
shown
develop
nonpathogen
rvsvng
vector
express
influenza
gene
rvsvng
vaccin
develop
ebov
marv
rvsvng
vector
modifi
carri
gp
gene
zebov
sebov
musok
strain
marv
place
vsv
g
protein
rvsvng
virus
express
filoviru
gp
exhibit
rhabdoviru
morpholog
unlik
rvsv
addit
transcript
unit
express
solubl
gp
virus
carri
foreign
transmembran
filoviru
gp
replac
vsv
g
slightli
attenu
growth
initi
studi
use
rvsvngbase
filoviru
vaccin
focus
abil
vaccin
protect
anim
homolog
filoviru
challeng
vaccin
balbc
mice
singl
intraperiton
inject
pfu
rvsvng
vector
express
zebov
gp
complet
protect
anim
lethal
mouseadapt
zebov
challeng
day
immun
likewis
singl
intramuscular
vaccin
cynomolgu
monkey
rvsvng
vector
express
zebov
gp
induc
strong
humor
cellular
immun
respons
vaccin
monkey
elicit
complet
protect
highdos
pfu
intramuscular
challeng
homolog
zebov
given
day
later
tabl
howev
crossprotect
subsequ
backchalleng
zebovsurviv
macaqu
sebov
result
fatal
diseas
rvsvng
zebov
vaccin
subsequ
test
highdos
pfu
aerosol
challeng
homolog
zebov
singl
intramuscular
vaccin
cynomolgu
monkey
rvsvng
zebov
gp
complet
protect
anim
homolog
aerosol
challeng
zebov
given
day
later
tabl
furthermor
protect
confer
rvsvng
zebov
gp
vaccin
via
variou
deliveri
rout
immun
either
balbc
mice
cynomolgu
monkey
rvsvng
zebov
gp
vaccin
either
intranas
oral
rout
result
complet
protect
anim
highdos
pfu
intramuscular
homolog
zebov
challeng
tabl
robust
zebov
gpspecif
humor
respons
tcell
respons
induc
vaccin
month
zebov
challeng
macaqu
vaccin
either
intranas
oral
rout
marv
singl
intramuscular
vaccin
cynomolgu
monkey
rvsvng
marvmusok
gp
vaccin
elicit
complet
protect
highdos
pfu
intramuscular
challeng
homolog
marv
given
day
later
tabl
anim
also
protect
rechalleng
marv
strain
day
later
furthermor
vaccin
prove
protect
genet
mostdispar
marv
strain
ravn
appear
mostvirul
strain
angola
suggest
may
confer
crossprotect
divers
strain
marv
tabl
zebov
recent
studi
show
singl
vaccin
cynomolgu
monkey
rvsvng
marvmusok
gp
complet
protect
anim
homolog
aerosol
challeng
marv
given
day
later
tabl
possibl
overlap
endem
filovirus
africa
well
threat
bioterror
would
ideal
singleinject
vaccin
could
protect
variou
speci
strain
ebov
marv
recent
studi
cynomolgu
monkey
vaccin
multival
blend
vaccin
consist
equal
part
rvsvng
gp
vaccin
marv
ebov
sebov
week
postvaccin
group
anim
challeng
marv
zebov
sebov
icebov
tabl
none
vaccin
macaqu
succumb
filoviru
challeng
show
great
promis
singleinject
multival
blend
platform
addit
util
prevent
vaccin
rvsvng
vaccin
platform
also
use
postexposur
treatment
filoviru
infect
tabl
treatment
rhesu
monkey
rvsvng
marvmusok
gp
shortli
homolog
highdos
marv
challeng
result
complet
protect
anim
clinic
ill
death
subsequ
studi
demonstr
rvsvng
gp
vaccin
zebov
sebov
protect
respect
rhesu
macaqu
administ
postexposur
prophylaxi
highdos
homolog
viru
challeng
vaccin
administ
studi
minut
filoviru
challeng
major
question
long
viru
exposur
rvsvng
vaccin
effect
recent
studi
treatment
rhesu
monkey
rvsvng
marvmusok
gp
hour
homolog
marv
challeng
result
protect
monkey
wherea
remark
anim
protect
vaccin
administ
hour
infect
main
concern
replicationcompet
vaccin
includ
rvsvng
platform
safeti
especi
person
compromis
immun
system
howev
initi
result
variou
rvsvng
rvsv
vector
nhp
promis
toxic
seen
rhesu
macaqu
follow
intranas
inocul
wildtyp
vsv
rvsv
rvsvhiv
vaccin
although
signific
neurovirul
note
anim
direct
intrathalam
inocul
rvsv
date
toxic
seen
nhp
given
rvsvng
marv
ebov
vaccin
furthermor
signific
vaccin
shed
seen
experi
despit
challeng
dose
pfu
suggest
along
natur
low
transmiss
vsv
spread
person
outsid
vaccin
target
popul
unlik
specif
address
safeti
rvsvngbase
filoviru
vaccin
rvsvng
zebov
gp
vaccin
evalu
anim
model
defect
immun
system
nonobes
diabeticsever
combin
immunodefici
nodscid
mice
simianhuman
immunodefici
shiv
infect
rhesu
monkey
immun
evid
overt
ill
note
anim
addit
rvsvng
zebov
gp
vaccin
recent
use
treat
laboratori
worker
recent
laboratori
accid
vaccin
administ
hour
potenti
zebov
exposur
patient
develop
fever
headach
myalgia
hour
inject
advers
effect
report
certain
infect
actual
occur
efficaci
vaccin
case
could
evalu
ensur
safeti
vsv
g
pathogen
wildtyp
vsv
may
attribut
delet
rvsvng
filoviru
vaccin
current
studi
perform
evalu
neurovirul
rvsvng
zebov
gp
rvsvng
marvmusok
vaccin
convent
intrathalam
neurovirul
assay
cynomolgu
monkey
regard
possibl
vaccin
viru
mutat
morevirul
variant
comfort
taken
note
case
live
measl
vaccin
use
unit
state
countri
sinc
review
evid
acquir
higher
pathogen
potenti
vaccin
develop
ebov
marv
success
preced
decad
gener
sever
promis
experiment
approach
tabl
rvsv
platform
shown
complet
efficaci
prevent
singleshot
vaccin
relev
anim
model
includ
gold
standard
nonhuman
primat
model
blend
cocktail
shown
complet
efficaci
prevent
vaccin
public
health
relev
filoviru
speci
partial
overlap
endem
zone
central
africa
final
platform
shown
partial
complet
efficaci
postexposur
treatment
homolog
filoviru
challeng
given
efficaci
profil
prevent
treatment
approach
safeti
record
sever
immunecompet
immunecompromis
anim
speci
vaccin
platform
readi
consid
investig
drug
licensur
propos
consid
rvsv
platform
preinvestig
drug
use
case
laboratori
exposur
ebov
marv
addit
ebov
marv
rvsvbase
vaccin
current
evalu
number
human
pathogen
includ
avian
influenza
hepat
b
hiv
lassa
fever
sever
acut
respiratori
syndrom
sar
west
nile
viru
yersinia
pesti
knowledg
gain
studi
advanc
develop
rvsvbase
vaccin
human
use
note
pfu
plaqueform
unit
nhp
nonhuman
primat
gp
glycoprotein
lake
victoria
marburgviru
marv
sudan
ebolaviru
z
zair
ebolaviru
